Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 2,721–2,730 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 2721

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    BCRP
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.

  2. Projected row 2722

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    CYP2C9
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      CYP3A4/2C9 Inducers Erdafitinib mean ratios for C max and AUC inf were 78% and 45%, respectively, when BALVERSA was co-administered with carbamazepine (a strong CYP3A4 and weak CYP2C9 inducer) relative to BALVERSA alone.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      CYP3A4/2C9 Inducers Erdafitinib mean ratios for C max and AUC inf were 78% and 45%, respectively, when BALVERSA was co-administered with carbamazepine (a strong CYP3A4 and weak CYP2C9 inducer) relative to BALVERSA alone.

  3. Projected row 2723

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    CYP2C9
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    1
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies Effect of Other Drugs on Erdafitinib Moderate CYP2C9 Inhibitors Erdafitinib mean ratios for C max and AUC inf were 121% and 148%, respectively, when BALVERSA was co-administered with fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, relative to BALVERSA administered alone.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies Effect of Other Drugs on Erdafitinib Moderate CYP2C9 Inhibitors Erdafitinib mean ratios for C max and AUC inf were 121% and 148%, respectively, when BALVERSA was co-administered with fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, relative to BALVERSA administered alone.
    3. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Acid-lowering agents (including antacids, H 2 -antagonists and proton pump inhibitors) are not expected to affect the bioavailability of erdafitinib. 12.5 Pharmacogenomics CYP2C9 activity is reduced in individuals with genetic variants, such as the CYP2C9*2 and CYP2C9*3 polymorphisms.

  4. Projected row 2724

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    CYP2C9
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    7
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Metabolism Erdafitinib is primarily metabolized by CYP2C9 and CYP3A4.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      The contribution of CYP2C9 and CYP3A4 in the total clearance of erdafitinib is estimated to be 39% and 20%, respectively.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Metabolism Erdafitinib is primarily metabolized by CYP2C9 and CYP3A4.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      The contribution of CYP2C9 and CYP3A4 in the total clearance of erdafitinib is estimated to be 39% and 20%, respectively.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib exposure was similar in subjects with CYP2C9*1/*2 and *1/*3 genotypes relative to subjects with CYP2C9*1/*1 genotype (wild type).
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Simulation suggested no clinically meaningful differences in erdafitinib exposure in subjects with CYP2C9*2/*2 and *2/*3 genotypes.
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      The exposure of erdafitinib is predicted to be 50% higher in subjects with the CYP2C9*3/*3 genotype, estimated to be present in 0.4% to 3% of the population among various ethnic groups.

  5. Projected row 2725

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    CYP3A4
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      CYP3A4/2C9 Inducers Erdafitinib mean ratios for C max and AUC inf were 78% and 45%, respectively, when BALVERSA was co-administered with carbamazepine (a strong CYP3A4 and weak CYP2C9 inducer) relative to BALVERSA alone.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      CYP3A4/2C9 Inducers Erdafitinib mean ratios for C max and AUC inf were 78% and 45%, respectively, when BALVERSA was co-administered with carbamazepine (a strong CYP3A4 and weak CYP2C9 inducer) relative to BALVERSA alone.

  6. Projected row 2726

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies Effect of Other Drugs on Erdafitinib Moderate CYP2C9 Inhibitors Erdafitinib mean ratios for C max and AUC inf were 121% and 148%, respectively, when BALVERSA was co-administered with fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, relative to BALVERSA administered alone.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inhibitors Erdafitinib mean ratios for C max and AUC inf were 105% and 134%, respectively, when BALVERSA was co-administered with itraconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) relative to BALVERSA alone.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies Effect of Other Drugs on Erdafitinib Moderate CYP2C9 Inhibitors Erdafitinib mean ratios for C max and AUC inf were 121% and 148%, respectively, when BALVERSA was co-administered with fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, relative to BALVERSA administered alone.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inhibitors Erdafitinib mean ratios for C max and AUC inf were 105% and 134%, respectively, when BALVERSA was co-administered with itraconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) relative to BALVERSA alone.

  7. Projected row 2727

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    8
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Metabolism Erdafitinib is primarily metabolized by CYP2C9 and CYP3A4.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      The contribution of CYP2C9 and CYP3A4 in the total clearance of erdafitinib is estimated to be 39% and 20%, respectively.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Effect of Erdafitinib on Other Drugs CYP3A4 Substrates: No clinically meaningful effect on the exposure of midazolam (a CYP3A4 substrate) was observed following coadministration with BALVERSA.
    4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      In Vitro Studies CYP Substrates Erdafitinib is a time dependent inhibitor and inducer of CYP3A4.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Metabolism Erdafitinib is primarily metabolized by CYP2C9 and CYP3A4.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      The contribution of CYP2C9 and CYP3A4 in the total clearance of erdafitinib is estimated to be 39% and 20%, respectively.
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Effect of Erdafitinib on Other Drugs CYP3A4 Substrates: No clinically meaningful effect on the exposure of midazolam (a CYP3A4 substrate) was observed following coadministration with BALVERSA.
    8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      In Vitro Studies CYP Substrates Erdafitinib is a time dependent inhibitor and inducer of CYP3A4.

  8. Projected row 2728

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    MATE-
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.

  9. Projected row 2729

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    MATE-1
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.

  10. Projected row 2730

    Medicine slug
    erdafitinib
    Medicine name
    Erdafitinib
    Enzyme or transporter
    OAT1
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee (opens source in a new tab)

      Erdafitinib label

      Version not recorded · Effective date not recorded

      Erdafitinib does not inhibit BCRP, OATP1B, OATP1B3, OAT1, OAT3, OCT1, MATE-1, or MATE-2K at clinically relevant concentrations.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=2720

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy
Enzyme and transporter findings | RNAWiki